Swift FDA Approval Can Complicate Reimbursement Efforts, Consultant Says
This article was originally published in The Gray Sheet
Executive Summary
Rapid FDA approval of Johnson & Johnson/Depuy's Charité artificial disc contributed to early reimbursement setbacks for the device, according to Quorum Consulting Senior Consultant Barbara Santry
You may also be interested in...
SpineMedica Predicts Lumbar Disc Market Entry In 2-3 Years With SaluDisc
Development-stage SpineMedica expects to reach the market with a hydrogel artificial lumbar disc in two to three years, according to President Matthew Miller
SpineMedica Predicts Lumbar Disc Market Entry In 2-3 Years With SaluDisc
Development-stage SpineMedica expects to reach the market with a hydrogel artificial lumbar disc in two to three years, according to President Matthew Miller
CMS Opens National Coverage Decision Request On Artificial Lumbar Discs
CMS is reviewing whether artificial lumbar discs should be nationally non-covered for Medicare beneficiaries after a physician urged the agency to open a national coverage decision request